Literature DB >> 15027062

Treatment of cervical dystonia with botulinum toxin.

Joseph Jankovic1.   

Abstract

Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double-blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027062     DOI: 10.1002/mds.20024

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 2.  Botulinum toxin therapy for cervical dystonia.

Authors:  J Jankovic
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: initial report.

Authors:  Hong Wu; Rizwana Sultana; Kerrey Barton Taylor; Aniko Szabo
Journal:  Clin J Pain       Date:  2012-02       Impact factor: 3.442

Review 4.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

5.  Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Authors:  Andre C Felicio; Clecio Godeiro-Junior; Patricia de Carvalho Aguiar; Vanderci Borges; Sonia M A Silva; Henrique B Ferraz
Journal:  Neurol Sci       Date:  2009-05-26       Impact factor: 3.307

6.  Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek; Lance E Steward; K Roger Aoki
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

Review 7.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A.

Authors:  D Tiple; S Strano; C Colosimo; G Fabbrini; G Calcagnini; M Prencipe; A Berardelli
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

Review 9.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

10.  Experience with long-term treatment with albumin-supplemented botulinum toxin type A.

Authors:  Bahram Mohammadi; Katja Kollewe; Maresa Wegener; Hans Bigalke; Reinhard Dengler
Journal:  J Neural Transm (Vienna)       Date:  2009-03-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.